About: Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
Creator	Conti, Pio Gallenga, Carla Kritas, Spyros Ronconi, Gianpaolo Aquili, Alberto Caraffa, Alessandro Farinelli, Luca Gigante, Antonio Tetè, Giulia
source	Elsevier; Medline; PMC
abstract	A novel human coronavirus SARS‐CoV‐2 (also referred to as CoV-19) that emerged in late 2019 causes Covid-19 disease a respiratory tract infection which provokes about 4 million deaths per year. Unfortunately, to date, there is no specific antiviral treatment for COVID-19. Mast cells (MCs) are immune cells implicated in the pathogenesis of viral infections, where they mediate inflammation. Microbes, including virus, activate MCs through TLR releasing chemical pro-inflammatory compounds and cytokines. Although, in biomedical literature there are only few reports on MCs activation by SARS-CoV-2 infection. The production of pro-inflammatory cytokines by MC viral activation leads to increase pulmonary inflammation and fibrosis. Sodium Chromo-Glycate (SCG) described as a MC stabilizer, prevents the release of inflammatory chemical compounds, improve mouse survival and respiratory pathological changes in lung viral infection and suppresses inflammation. Furthermore, palmitoylethanolamide (PEA) a nuclear factor agonist, an endogenous fatty acid amide, which exerts a variety of biological effects, related to chronic inflammation and pain, is involved also in MCs homeostasis with an inhibitory and protective effect on the respiratory tract during viral infections. Here, we hypothesize for the first time, that SCG and/or PEA suppress MC activation and pro-inflammatory mediators release, playing an anti-inflammatory therapeutic role in the inflamed lung of patients with COVID-19.
has issue date	2020-05-19(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.109856
bibo:pmid	32460208
has license	no-cc
sha1sum (hex)	ff9267dfa442a46bc98e5e983a8032991931bd51
schema:url	https://doi.org/10.1016/j.mehy.2020.109856
resource representing a document's title	Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
has PubMed Central identifier	PMC7236677
has PubMed identifier	32460208
schema:publication	Med Hypotheses
resource representing a document's body	covid:ff9267dfa442a46bc98e5e983a8032991931bd51#body_text
is schema:about of	named entity 'Sodium' named entity 'COVID-19' named entity 'Sodium' named entity 'Glycate' named entity 'SARS' named entity 'world's population' named entity 'clinical practice' named entity 'homeostasis' named entity 'COX-2' named entity 'pathogen-associated molecular patterns' named entity 'RNA viruses' named entity 'transcription factors' named entity 'clinical studies' named entity 'Toll-like receptors' named entity 'histamine' named entity 'oxygen' named entity 'epithelial layer' named entity 'SCG' named entity 'fibrosis' named entity 'lung' named entity 'SCG' named entity 'infection' named entity 'respiratory infections' named entity 'down-regulate' named entity 'SARS-CoV' named entity 'MDA5' named entity 'immune response' named entity 'hemorrhage' named entity 'inflammatory' named entity 'blood vessels' named entity 'nucleus' named entity 'lungs' named entity 'lung' named entity 'influenza virus' named entity 'respiratory tract' named entity 'influenza virus' named entity 'infection' named entity 'interstitial pneumonia' named entity 'inflammatory mediators' named entity 'SCG' named entity 'SCG' named entity 'dose-dependent manner' named entity 'IL-6' named entity 'PRRs' named entity 'analgesic' named entity 'COVID' named entity 'hyperactive' named entity 'alveolar' named entity 'viral infections' named entity 'tissue damage' named entity 'Wuhan' named entity 'systematic review' named entity 'mast cells' named entity 'inflammatory response' named entity 'innate immune response' named entity 'influenza' named entity 'viral infections' named entity 'MERS-CoV' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'lungs' named entity 'ARDS' named entity 'mucopurulent' named entity 'hyaline' named entity 'iNOS' named entity 'antiviral treatment' named entity 'lungs' named entity 'inflammatory response' named entity 'coronaviruses' named entity 'anti-inflammatory' named entity 'fatty acid amide' named entity 'endogenous' named entity 'PRRs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software